ES2227115T5 - Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia - Google Patents

Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia Download PDF

Info

Publication number
ES2227115T5
ES2227115T5 ES01900978.6T ES01900978T ES2227115T5 ES 2227115 T5 ES2227115 T5 ES 2227115T5 ES 01900978 T ES01900978 T ES 01900978T ES 2227115 T5 ES2227115 T5 ES 2227115T5
Authority
ES
Spain
Prior art keywords
hypertriglyceridemia
agonists
exendins
levels
triglyceride levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01900978.6T
Other languages
English (en)
Spanish (es)
Other versions
ES2227115T3 (es
Inventor
Orville Gene Kolterman
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22639978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2227115(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2227115T3 publication Critical patent/ES2227115T3/es
Publication of ES2227115T5 publication Critical patent/ES2227115T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES01900978.6T 2000-01-10 2001-01-09 Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia Expired - Lifetime ES2227115T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17536500P 2000-01-10 2000-01-10
US175365P 2000-01-10
PCT/US2001/000719 WO2001051078A1 (en) 2000-01-10 2001-01-09 Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia

Publications (2)

Publication Number Publication Date
ES2227115T3 ES2227115T3 (es) 2005-04-01
ES2227115T5 true ES2227115T5 (es) 2014-10-30

Family

ID=22639978

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01900978.6T Expired - Lifetime ES2227115T5 (es) 2000-01-10 2001-01-09 Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia

Country Status (11)

Country Link
US (1) US20030036504A1 (enExample)
EP (1) EP1246638B2 (enExample)
JP (1) JP2003519667A (enExample)
AT (1) ATE275967T1 (enExample)
AU (1) AU2006202247A1 (enExample)
CA (1) CA2396157A1 (enExample)
DE (1) DE60105547T3 (enExample)
DK (1) DK1246638T4 (enExample)
ES (1) ES2227115T5 (enExample)
PT (1) PT1246638E (enExample)
WO (1) WO2001051078A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US20030040469A1 (en) * 2000-03-08 2003-02-27 Knudsen Liselotte Bjerre Lowering serum lipids
EP1263458B1 (en) * 2000-03-08 2005-11-16 Novo Nordisk A/S Lowering serum cholesterol
EP2022505B1 (en) 2001-07-31 2011-12-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
CN100350968C (zh) 2001-09-24 2007-11-28 皇家创新有限公司 饮食行为的改进
JP4733922B2 (ja) 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
US20060190425A1 (en) * 2005-02-24 2006-08-24 Yuan-Chi Chang Method for merging multiple ranked lists with bounded memory
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
TWI364292B (en) 2005-06-30 2012-05-21 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007024700A2 (en) 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
AU2008297954A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Minigastrin as a therapeutic agent
AU2008306141A1 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
US20110263496A1 (en) * 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
UA104866C2 (uk) * 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
EP2435061A4 (en) 2009-05-28 2013-03-27 Amylin Pharmaceuticals Inc DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US9161953B2 (en) 2010-12-22 2015-10-20 Amylin Pharmaceuticals, Llc GLP-1 receptor agonists for islet cell transplantation
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX362190B (es) 2012-12-21 2019-01-08 Sanofi Sa Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2018071528A1 (en) * 2016-10-11 2018-04-19 University Of Georgia Research Foundation, Inc. Proteins and method for treating obesity and associated comorbidities
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JP7309606B2 (ja) * 2016-12-22 2023-07-18 サノフイ 活性比が最適化されたｆｇｆ２１化合物／ｇｌｐ－１ｒアゴニスト組合せ物
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
EP3642238A1 (en) 2017-06-21 2020-04-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
EP3934679A1 (en) 2019-03-08 2022-01-12 Amgen Inc. Growth differentiation factor 15 combination therapy
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
WO1998030231A1 (en) * 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
KR20010033017A (ko) * 1997-12-12 2001-04-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 과지질혈증 치료제인 스타틴-ＬＰ(ａ) 억제제의 병용 제제
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
CA2372214A1 (en) * 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists

Also Published As

Publication number Publication date
HK1050477A1 (en) 2003-06-27
AU784488B2 (en) 2006-04-13
DE60105547T3 (de) 2014-12-31
DK1246638T3 (da) 2005-01-10
DE60105547T2 (de) 2005-10-13
PT1246638E (pt) 2004-12-31
AU2638001A (en) 2001-07-24
EP1246638A1 (en) 2002-10-09
US20030036504A1 (en) 2003-02-20
AU2006202247A1 (en) 2006-06-22
EP1246638B2 (en) 2014-07-30
CA2396157A1 (en) 2001-07-19
ES2227115T3 (es) 2005-04-01
DK1246638T4 (da) 2014-09-22
ATE275967T1 (de) 2004-10-15
JP2003519667A (ja) 2003-06-24
EP1246638B1 (en) 2004-09-15
DE60105547D1 (de) 2004-10-21
WO2001051078A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
ES2227115T5 (es) Utilización de exendinas y sus agonistas para el tratamiento de la hipertrigliceridemia
US6939853B2 (en) Combined use of a GLP-1 compound and another drug for treating dyslipidemia
ES2280596T3 (es) Uso combinado de un compuesto de glp-1 y un inhibidor de una aldosa reductasa.
US7569546B2 (en) Apolipoprotein A1 mimetics and uses thereof
JP2014159431A (ja) 血糖降下剤の投与方法
US9062093B2 (en) Peptide compositions and methods for treating patients
WO2010121352A1 (en) Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
JP6053945B2 (ja) 肥満症、糖尿病、高血圧症及び高脂血症を治療するための局所薬としてのスタチン化合物の使用
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
US20200345683A1 (en) Composition compromising dunnione as effective ingredient for prevention or alleviation of hair loss
EP1474164A2 (en) Use of amylin agonists to modulate triglycerides
ES2201128T3 (es) Agente terapeutico para alteraciones del metabolismo de lipidos.
US20250288650A1 (en) Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist
JP2007519669A (ja) 脂肪異栄養症を治療するための方法及び組成物
WO2025076208A9 (en) Compositions and methods for treating pain disorders
JP2017532292A (ja) ミリストイル化レプチン関連ペプチド及びその使用
WO2025120001A1 (en) Amylin analogues for reducing consumption of high-fat food
JP2013121936A (ja) 肥満・メタボリックシンドローム治療薬、及びその動物の治療方法
Mouihate et al. FINAL ACCEPTED VERSION R-00250-2006. R1
US20140235545A1 (en) The use of HCV immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy
JPH08157492A (ja) 抗動脈硬化ペプチド
HK1096314A (en) Methods and compositions for the treatment of lipodystrophy
WO2010121351A1 (en) Use of (hexenoyl trans-3)hgrf(1-44)nh2 and ritonavir in combination therapy
RU2005131951A (ru) Способ повышения пероральной биодоступности s-[2-([[1-(2-этилбутил)циклогексил]карбонил]амино)фенил]-2-метилпропантиоата